{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:52:34Z","timestamp":1793159554549,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T00:00:00Z","timestamp":1478908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Spironolactone is widely used to treat heart failure, hypertension and liver disease with increased usage in recent years. Spironolactone has endocrine effects that could influence cancer risks and historical reports suggest possible links with increased risk of certain types of cancer. The aim of this study was to assess the effect of spironolactone exposure on cancer incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pharmacoepidemiological propensity score\u2010matched cohort study was performed to assess the effect of spironolactone exposure on cancer incidence. Cox proportional hazards models were used to analyse time to first diagnosis of each prespecified cancer and hazard ratios for spironolactone exposure are presented. The setting for the study was UK primary care using the Clinical Practice Research Datalink. The participants were 74 272 patients exposed to spironolactone between 1986 and 2013, matched 1:2 with unexposed controls. The prespecified primary outcomes were the first incidence of ovarian, endometrial, pancreatic, colorectal, prostate, renal cell, pharyngeal and thyroid cancers, and myelomonoblastic\/\u2010cytic leukaemias. Secondary outcomes were the remaining 27 types of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no evidence of an increased risk of any cancer associated with spironolactone use. Spironolactone use was associated with a significantly lower risk of prostate cancer (hazard ratio 0.69; 95% confidence interval 0.60\u20130.80,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, spironolactone use was associated with a lower incidence of prostate cancer, the most common cancer in men in the UK. The possible mechanisms and clinical implications merit further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.13152","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T20:58:46Z","timestamp":1476392326000},"page":"653-663","source":"Crossref","is-referenced-by-count":49,"title":["Spironolactone use and risk of incident cancers: a retrospective, matched cohort study"],"prefix":"10.1111","volume":"83","author":[{"given":"Isla S.","family":"Mackenzie","sequence":"first","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), Division of Molecular and Clinical Medicine University of Dundee  Dundee DD1 9SY UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven V.","family":"Morant","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), Division of Molecular and Clinical Medicine University of Dundee  Dundee DD1 9SY UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy University College London  Gower Street London WC1E 6BT UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, FCT7.6092 University of Texas MD Anderson Cancer Center  1400 Pressler Street Houston Texas 77030 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit (MEMO), Division of Molecular and Clinical Medicine University of Dundee  Dundee DD1 9SY UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1768"},{"key":"e_1_2_9_3_1","unstructured":"NICE Clinical Guideline CG127: Hypertension: Clinical management of primary hypertension in adults. National Institute for Health and Care Excellence 2011. Available athttp:\/\/publications.nice.org.uk\/hypertension\u2010cg127#(last accessed 08\/04\/2014)."},{"key":"e_1_2_9_4_1","unstructured":"Spironolactone.British National Formulary April 2014. Available athttp:\/\/www.medicinescomplete.com\/mc\/bnf\/current\/PHP834\u2010spironolactone.htm(last accessed 08\/04\/2014)."},{"key":"e_1_2_9_5_1","unstructured":"IARC Monographs Volume 79: Spironolactone. P319\u2013337. Available athttp:\/\/monographs.iarc.fr\/ENG\/Monographs\/vol79\/mono79\u201013.pdf(last accessed 17th March 2014)."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03339.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90295-6"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(99)00251-8"},{"key":"e_1_2_9_9_1","first-page":"5736","article-title":"Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow\u2010up","volume":"49","author":"Selby JV","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_9_10_1","first-page":"1","article-title":"A population\u2010based case\u2013control study of thyroid cancer","volume":"79","author":"Ron E","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630212"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/23.5.923"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009848"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a117328"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.248"},{"key":"e_1_2_9_16_1","first-page":"128","article-title":"Breast cancer in the male \u2013 a retrospective analysis of 15 cases","volume":"13","author":"Stierer M","year":"1990","journal-title":"Onkologie"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92645-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92814-7"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)93258-9"},{"key":"e_1_2_9_20_1","first-page":"669","article-title":"Reserpine and breast cancer","volume":"2","author":"Boston Collaborative Drug Surveillance Program","year":"1974","journal-title":"Lancet"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113416"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-001-0152-4"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4447"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.10.004"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4037\/ajcc2004.13.2.162","article-title":"The resurrection of spironolactone on its golden anniversary","volume":"13","author":"Futterman LG","year":"2004","journal-title":"Am J Crit Care"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04248-7"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_9_28_1","unstructured":"Cancer Research UK.Prostate cancer statistics. Available athttp:\/\/www.cancerresearchuk.org\/health\u2010professional\/cancer\u2010statistics\/statistics\u2010by\u2010cancer\u2010type\/prostate\u2010cancer#heading\u2010Zero(last accessed 22\/04\/2016)"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215932"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku217"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122292"},{"key":"e_1_2_9_32_1","unstructured":"NICE Clinical Guideline CG175: Prostate cancer: diagnosis and treatment. National Institute for Health and Care Excellence 2014. Available atguidance.nice.org.uk\/cg175(last accessed 08\/04\/2014)."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5238"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:54:19Z","timestamp":1696240459000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bcp.13152"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13152","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726842477.793536584","asserted-by":"object"}]},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,12]]}}}